Delaware
|
|
000-29169
|
|
98-0178636
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S Employer Identification No.)
|
33 Harbour Square, Suite 202, Toronto, Ontario Canada
|
|
M5J 2G2
|
(Address of principal executive offices)
|
|
(Zip Code)
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(d)
|
Exhibits.
|
Exhibit
Number
|
Description
|
|
99.1
|
Press release issued by Generex Biotechnology Corporation dated March 30, 2011.
|
|
GENEREX BIOTECHNOLOGY CORPORATION.
|
||||||
Date: March 30, 2011
|
/s/ Mark A. Fletcher
|
|||||
Mark A. Fletcher
President and Chief Executive Officer
|
Exhibit
Number
|
Description
|
|
99.1
|
Press release issued by Generex Biotechnology Corporation dated March 30, 2011.
|